Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine Capsule vs Patch in Parkinson's Disease Dementia
NCT00623103Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2008
- Primary completion
- Nov 2010
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of rivastigmine in Parkinson's disease dementia (PDD), sponsored by Novartis. Primary endpoint: Percentage of Participants With Adverse Events Due, or Potentially Due, to Worsening of Parkinson Disease Motor Symptoms at 76 weeks. Started Jan 2008; status: completed.
02
Drugs
rivastigmine
03
Conditions
Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT00623103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00623103.